# A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

Source: https://onco.cc/trials/nct02519348/  
OnCo record `nct02519348` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Tremelimumab, Durvalumab, Bevacizumab in hepatocellular carcinoma, run by MedImmune LLC, active and no longer recruiting.

## Summary

A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma is a phase 2 interventional study registered as NCT02519348 by MedImmune LLC, with 433 participants enrolled, started 2015-10-19 and due to reach its primary completion in 2020-11-06. Interventions recorded: Tremelimumab, Durvalumab, Bevacizumab. Conditions listed: Hepatocellular Carcinoma. Results were posted on ClinicalTrials.gov in 2021; the figures recorded here are the registry's, not a publication's.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Tags: ctgov-ingest
- Registry id: NCT02519348
- Phase: 2
- Setting: A Study of Safety, Tolerability, and Clinical Activity of Durvalumab and Tremelimumab Administered as Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Subjects With Advanced Hepatocellular Carcinoma
- Sponsor: MedImmune LLC
- Enrolled: 433
- Outcomes: Number of Participants With Dose Limiting Toxicities (DLTs): Part 1A: Tremelimumab 1 mg/kg + Durvalumab 20 mg/kg 0 participants; Overall Survival (OS): Part 1: Tremelimumab 1 mg/kg + Durvalumab 20 mg/kg 12.58 months vs Parts 2 and 3: Durvalumab 1500 mg 12.91 months vs Parts 2 and 3: Tremelimumab 300 mg + Durvalumab 1500 mg 17.05 months vs Parts 2 and 3: Tremelimumab 750 mg 17.05 months vs Parts 2 and 3: Tremelimumab 75 mg + Durvalumab 1500 mg 11.3 months vs Part 4: Durvalumab 1120 mg + Bevacizumab 15 mg/kg vs China Cohort: Durvalumab 20 mg/kg 30.69 months vs China Cohort: Tremelimumab 10 mg/kg 3.52 months vs China Cohort: Tremelimumab 1 mg/kg + Durvalumab 20 mg/kg 6.28 months

## Sources

- ClinicalTrials.gov NCT02519348: https://clinicaltrials.gov/study/NCT02519348

## Connected records

- cancers: [Advanced hepatocellular carcinoma (BCLC C)](https://onco.cc/cancers/hcc-advanced/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Tremelimumab](https://onco.cc/drugs/tremelimumab/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct02519348.json